Short Interest in Defence Therapeutics Inc. (OTCMKTS:DTCFF) Decreases By 96.6%

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 100 shares, a decrease of 96.6% from the February 13th total of 2,900 shares. Based on an average daily trading volume, of 10,600 shares, the days-to-cover ratio is currently 0.0 days.

Defence Therapeutics Price Performance

OTCMKTS DTCFF traded up $0.07 during trading on Wednesday, hitting $1.00. 900 shares of the company traded hands, compared to its average volume of 20,078. The business has a fifty day simple moving average of $0.70 and a 200 day simple moving average of $0.51. Defence Therapeutics has a 12 month low of $0.27 and a 12 month high of $1.32.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.